The group will start a pivotal trial of samuraciclib following promising second-line results.
ApexOnco Front Page
Recent articles
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
The pivotal Harmoni-GI3 study has started enrolling patients.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH and SABCS approach.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
The project has priority review, but deaths could raise eyebrows.
